GlassScriptPhysician profile
Leanne M Hedges
NPI 1346470036
$3,680.22
in general payments reported to CMS, 2019-2025
34 companies · $221 in 2025
The $221 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,639 · 2022: $984 · 2023: $451 · 2024: $386 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,057.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,057.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,169.07 | 2021-2025 | |
| Novo Nordisk INC | $354.71 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $288.84 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $227.51 | 2021-2022 | |
| Corium, LLC | $147.27 | 2022-2024 | Azstarys |
| Biohaven Pharmaceutical Holding Company LTD. | $107.83 | 2022 | |
| Exact Sciences Corporation | $103.42 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $94.78 | 2021-2025 | Capvaxive |
| Astellas Pharma US INC | $89.77 | 2021-2023 | Veozah |
| Sanofi-Aventis U.S. LLC | $86.77 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $78.68 | 2021-2022 | |
| Amarin Pharma, INC. | $78.42 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $78.14 | 2021-2022 | |
| Pfizer INC. | $76.47 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $66.32 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $60.10 | 2021-2025 | Trelegy Ellipta |
| Amgen INC. | $54.64 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $54.08 | 2022-2023 | Breztri |
| Bausch Health US, LLC | $52.83 | 2021-2025 | Aplenzin |
| Eisai INC. | $52.65 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $44.53 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $38.58 | 2021 | |
| Nevro Corp. | $34.88 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.74 | 2021-2025 | Xifaxan |
| Lundbeck LLC | $32.24 | 2021 | |
| Biogen, INC. | $27.47 | 2025 | Qalsody |
| Almatica Pharma LLC | $26.03 | 2021 | |
| Ironwood Pharmaceuticals, INC | $25.65 | 2021-2022 | |
| Grifols USA, LLC | $19.39 | 2021 | |
| Jazz Pharmaceuticals INC. | $18.95 | 2021 | |
| Electromed, INC. | $17.26 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.22 | 2021 | |
| Seqirus USA INC | $13.08 | 2021 | |
| Abbott Laboratories | $12.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leanne Hedges listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.